APA (7th ed.) Citation

Wlodarczyk, J., Hunsche, E., Silberberg, B., Kemp, D., Anell, B., Corcoran, K., . . . Beaudet, A. (2016). PRS46 - Cost-Effectiveness Analysis of Selexipag Versus Inhaled Iloprost In The Treatment of Pulmonary Arterial Hypertension (PAH) In Sweden. Value in Health, 19(7), A556. https://doi.org/10.1016/j.jval.2016.09.1214

Chicago Style (17th ed.) Citation

Wlodarczyk, J., E. Hunsche, B. Silberberg, D. Kemp, B. Anell, K. Corcoran, R. Minacori, M. Stevenson, and A. Beaudet. "PRS46 - Cost-Effectiveness Analysis of Selexipag Versus Inhaled Iloprost In The Treatment of Pulmonary Arterial Hypertension (PAH) In Sweden." Value in Health 19, no. 7 (2016): A556. https://doi.org/10.1016/j.jval.2016.09.1214.

MLA (9th ed.) Citation

Wlodarczyk, J., et al. "PRS46 - Cost-Effectiveness Analysis of Selexipag Versus Inhaled Iloprost In The Treatment of Pulmonary Arterial Hypertension (PAH) In Sweden." Value in Health, vol. 19, no. 7, 2016, p. A556, https://doi.org/10.1016/j.jval.2016.09.1214.